Bayer has begun production of Nifedipine, a compound used to treat angina and reduce arterial hypertension, at its plant in Asturias, Spain. The production of Nifedipine has been moved from Germany to Asturias, where the plant already produces Bayer's Acetylsalicylic Acid (Aspirin) and other key products. This move is seen as a step towards consolidating the plant's current activity and future growth. The new production line is expected to be operational by the end of 2021 and will be attended by the Minister of Health, Consumer Affairs and Social Welfare, Carolina Darias.
Bayer begins production in Asturias of Nifedipine, a compound used to relieve angina and reduce arterial hypertension. Production is being moved from Germany to Asturias. The Asturias plant produces 100% of Bayer's Acetylsalicylic Acid (Aspirin) and other key products. Nifedipine (Adelat) will be the sixth active ingredient to leave the facilities of the Bayer plant in Langreo.
In this way, Bayer said, the Asturian production center is "making progress in its contribution to the health of people around the world, and is now taking a new step that consolidates its current activity and its projection into the future."
Last February, when the Environmental Affairs Commission gave the multinational permission to produce Nifedipine at the Langreo plant, the company then set to work with the forecast that the new production line could be operational by the end of 2021.
The commissioning of the new production line will be attended by the Minister of Health, Consumer Affairs and Social Welfare, Carolina Darias, who will be accompanied by the CEO of Bayer in Spain and Portugal, Bernardo Kanauhati, and the director of the Llaner plant, Jorge Álvarez, as well as representatives of the government of the Principality.
News article based on 'Invest in Asturias' twitter feed